首页 > 最新文献

International journal of hematology-oncology and stem cell research最新文献

英文 中文
Determining the FY*BES Allele in Iranian Sickle Cell Disease Patients to Enhance Matching Blood Transfusion. 伊朗镰状细胞病患者FY*BES等位基因检测提高输血配型
Pub Date : 2025-01-01 DOI: 10.18502/ijhoscr.v19i1.17818
Mina Samadi Ivriq, Arezoo Oodi, Saeed Mohammadi, Bijan Keikhaei-Dehdazi, Moharram Ahmadnezhad, Sahar Jolharnejad

Background: Duffy antibodies play a significant role in hemolytic transfusion reactions and hemolytic disease of the fetus and newborn, Duffy(FY) blood group genotyping an essential part of transfusion medicine. The purpose of this study was to assess the importance of Duffy (FY) DNA typing in conducting transfusion compatibility testing and improving Red Blood Cell matching during transfusion. Materials and Methods: In this study, 135 blood samples from SCD patients from the Southwest of Iran were included. All samples were tested with Anti-Fya and Anti-Fyb using the hemagglutination technique, and 64 samples with the fy(a+b-) and fy(a-b-) phenotypes were genotyped using DNA sequencing methods. Results: The prevalence of alloimmunization in this population was 13.04%. fy(a-b+) was the most common phenotype (37/135, 27.4%), followed by fy(a+b-) (35/135, 26%), fy(a+b+) (34/135, 25.2%); and fy(a-b-) (29/135, 21.4%). Among the 64 fy(a+b-) and fy(a-b-) samples, 40 (62.5%) patients had FY*BES allele. 21 out of 40 samples were FY*BES/FY*BES, 17 were FY*A/FY*BES, and 2 were FY*B/FY*BES. Conclusion: The prevalence of GATA-1 mutation (FY*BES allele), in fy(a-b-) and fy(a+b-) patients was reported 62.5%. Therefore, it is possible to use the genotypic information as a database to facilitate the process of searching and supplying better-matched blood transfusion.

背景:达菲抗体在胎儿和新生儿的溶血性输血反应和溶血性疾病中起着重要作用,达菲血型基因分型是输血医学的重要组成部分。本研究的目的是评估达菲(FY) DNA分型在进行输血相容性测试和改善输血过程中的红细胞匹配中的重要性。材料和方法:本研究纳入了伊朗西南部SCD患者的135份血液样本。采用血凝技术对所有样品进行Anti-Fya和Anti-Fyb检测,并采用DNA测序方法对64份具有fy(a+b-)和fy(a-b-)表型的样品进行基因分型。结果:该人群异体免疫检出率为13.04%。Fy (a-b+)是最常见的表型(37/135,27.4%),其次是Fy (a+b-) (35/135, 26%), Fy (a+b+) (34/135, 25.2%);还有fy(a-b-) (29/ 135,21.4%)64例fy(a+b-)和fy(a-b-)样本中,40例(62.5%)患者携带fy *BES等位基因。40例样本中,FY*BES/FY*BES 21例,FY*A/FY*BES 17例,FY*B/FY*BES 2例。结论:GATA-1突变(FY*BES等位基因)在FY (a-b-)和FY (a+b-)患者中的患病率为62.5%。因此,有可能使用基因型信息作为数据库,以促进搜索和提供更好匹配的输血过程。
{"title":"Determining the <i>FY*BES</i> Allele in Iranian Sickle Cell Disease Patients to Enhance Matching Blood Transfusion.","authors":"Mina Samadi Ivriq, Arezoo Oodi, Saeed Mohammadi, Bijan Keikhaei-Dehdazi, Moharram Ahmadnezhad, Sahar Jolharnejad","doi":"10.18502/ijhoscr.v19i1.17818","DOIUrl":"10.18502/ijhoscr.v19i1.17818","url":null,"abstract":"<p><p><b>Background:</b> Duffy antibodies play a significant role in hemolytic transfusion reactions and hemolytic disease of the fetus and newborn, Duffy(<i>FY</i>) blood group genotyping an essential part of transfusion medicine. The purpose of this study was to assess the importance of Duffy (<i>FY</i>) DNA typing in conducting transfusion compatibility testing and improving Red Blood Cell matching during transfusion. <b>Materials and Methods:</b> In this study, 135 blood samples from SCD patients from the Southwest of Iran were included. All samples were tested with Anti-Fya and Anti-Fyb using the hemagglutination technique, and 64 samples with the fy(a+b-) and fy(a-b-) phenotypes were genotyped using DNA sequencing methods. <b>Results:</b> The prevalence of alloimmunization in this population was 13.04%. fy(a-b+) was the most common phenotype (37/135, 27.4%), followed by fy(a+b-) (35/135, 26%), fy(a+b+) (34/135, 25.2%); and fy(a-b-) (29/135, 21.4%). Among the 64 fy(a+b-) and fy(a-b-) samples, 40 (62.5%) patients had <i>FY*BES</i> allele. 21 out of 40 samples were <i>FY*BES/FY*BES</i>, 17 were <i>FY*A/FY*BES</i>, and 2 were <i>FY*B/FY*BES</i>. <b>Conclusion:</b> The prevalence of GATA-1 mutation (<i>FY*BES</i> allele), in fy(a-b-) and fy(a+b-) patients was reported 62.5%. Therefore, it is possible to use the genotypic information as a database to facilitate the process of searching and supplying better-matched blood transfusion.</p>","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"19 1","pages":"1-6"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12103832/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144153067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Minimal Residual Disease in Acute Lymphoblastic Leukaemia and Its Relationship with Other Prognostic Factors. 急性淋巴细胞白血病微小残留病及其与其他预后因素的关系。
Pub Date : 2025-01-01 DOI: 10.18502/ijhoscr.v19i1.17822
Chinmayee Agrawal, Sai Madhuri Boppana, Santhosh K Devdas, Vinayak V Maka, Nalini Kilara, Swaratika Majumdar, Rasmi Palassery

Background: Minimal Residual Disease (MRD) assessment is crucial for directing treatment decisions in Acute Lymphoblastic Leukemia (ALL). In low- and middle-income countries, limited resources can present challenges to implementing MRD-guided therapy intensification for ALL. The study attempted to assess the relationship between MRD and other prognostic factors in ALL, focusing on treatment outcomes and disease progression. Materials and Methods: A retrospective observational study was conducted at Ramaiah Medical College and Hospital in Bengaluru, examining patient data from January 2021 to December 2021. MRD status was determined post-induction using flow cytometry. Patients were classified into various groups based on factors such as type of ALL (B-cell or T-cell), NCI risk status (standard or high), cytogenetic risk (favorable, poor, or intermediate), CNS status, prednisone response, and MRD levels at the end of induction. Results: Out of 72 patients, 25% were MRD-positive, with a male: female ratio of 2.13:1. B-ALL was diagnosed in 49 patients and T-ALL in 23, with 75% categorized as high-risk by NCI criteria. Cytogenetic analysis revealed a diverse profile (23.61% PR, 48.61% IR, 27.78% FR), and 58.33% exhibited a good prednisone response (GPR). At the end of the induction phase, 25% tested positive for MRD, with B-ALL showing a lower MRD rate at 15.2%. Age and NCI risk status significantly influenced MRD outcomes, with 75% of participants classified as high-risk. Conclusion: This study demonstrates a significant association between MRD positivity and factors such as age, NCI risk status, and B-ALL diagnosis, underscoring the complex interaction of these variables in predicting treatment outcomes for ALL patients.

背景:极小残留病(MRD)评估对于指导急性淋巴细胞白血病(ALL)的治疗决策至关重要。在低收入和中等收入国家,有限的资源可能对实施耐药指导的ALL强化治疗带来挑战。该研究试图评估ALL中MRD与其他预后因素之间的关系,重点关注治疗结果和疾病进展。材料和方法:在班加罗尔的Ramaiah医学院和医院进行了一项回顾性观察研究,检查了2021年1月至2021年12月的患者数据。诱导后用流式细胞术检测MRD状态。根据ALL类型(b细胞或t细胞)、NCI风险状态(标准或高)、细胞遗传学风险(有利、差或中等)、中枢神经系统状态、泼尼松反应和诱导结束时的MRD水平等因素将患者分为不同的组。结果:72例患者中mrd阳性25%,男女比例为2.13:1。49例诊断为B-ALL, 23例诊断为T-ALL,其中75%根据NCI标准被归类为高风险。细胞遗传学分析显示不同的谱(23.61% PR, 48.61% IR, 27.78% FR), 58.33%表现出良好的泼尼松反应(GPR)。在诱导期结束时,25%的患者MRD检测呈阳性,B-ALL的MRD率较低,为15.2%。年龄和NCI风险状态显著影响MRD结果,75%的参与者被归类为高风险。结论:本研究表明MRD阳性与年龄、NCI风险状态和B-ALL诊断等因素之间存在显著关联,强调了这些变量在预测ALL患者治疗结果方面的复杂相互作用。
{"title":"Minimal Residual Disease in Acute Lymphoblastic Leukaemia and Its Relationship with Other Prognostic Factors.","authors":"Chinmayee Agrawal, Sai Madhuri Boppana, Santhosh K Devdas, Vinayak V Maka, Nalini Kilara, Swaratika Majumdar, Rasmi Palassery","doi":"10.18502/ijhoscr.v19i1.17822","DOIUrl":"10.18502/ijhoscr.v19i1.17822","url":null,"abstract":"<p><p><b>Background</b>: Minimal Residual Disease (MRD) assessment is crucial for directing treatment decisions in Acute Lymphoblastic Leukemia (ALL). In low- and middle-income countries, limited resources can present challenges to implementing MRD-guided therapy intensification for ALL. The study attempted to assess the relationship between MRD and other prognostic factors in ALL, focusing on treatment outcomes and disease progression. <b>Materials and Methods:</b> A retrospective observational study was conducted at Ramaiah Medical College and Hospital in Bengaluru, examining patient data from January 2021 to December 2021. MRD status was determined post-induction using flow cytometry. Patients were classified into various groups based on factors such as type of ALL (B-cell or T-cell), NCI risk status (standard or high), cytogenetic risk (favorable, poor, or intermediate), CNS status, prednisone response, and MRD levels at the end of induction. <b>Results:</b> Out of 72 patients, 25% were MRD-positive, with a male: female ratio of 2.13:1. B-ALL was diagnosed in 49 patients and T-ALL in 23, with 75% categorized as high-risk by NCI criteria. Cytogenetic analysis revealed a diverse profile (23.61% PR, 48.61% IR, 27.78% FR), and 58.33% exhibited a good prednisone response (GPR). At the end of the induction phase, 25% tested positive for MRD, with B-ALL showing a lower MRD rate at 15.2%. Age and NCI risk status significantly influenced MRD outcomes, with 75% of participants classified as high-risk. <b>Conclusion:</b> This study demonstrates a significant association between MRD positivity and factors such as age, NCI risk status, and B-ALL diagnosis, underscoring the complex interaction of these variables in predicting treatment outcomes for ALL patients.</p>","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"19 1","pages":"37-42"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12103823/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144153072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
OCT4 and Nestin Expression in the Microenvironment of Primary Central Nervous System Lymphomas. OCT4和Nestin在原发性中枢神经系统淋巴瘤微环境中的表达。
Pub Date : 2025-01-01 DOI: 10.18502/ijhoscr.v19i1.17823
Ana Laura Calderón-Garcidueñas, Diana Adixa García-Trejo, Noemi Gelista-Herrera, Israel Torres-Ramírez de Arellano

Background: Angiogenesis is essential for the survival of neoplasms. Our aim was to describe the clinical profile of primary central nervous system lymphoma (PCNSL) patients at our institution and explore the immunohistochemical expression of OCT4 and nestin in the tumor microenvironment especially in relation to angiogenesis. Materials and Methods: All cases of PCNSL from 2016 to 2022 were retrospectively studied, and clinical and radiological characteristics of the patients were obtained. Descriptive statistics were used. Results: 26 cases were studied; 24 cases (92.3%) were B-cell lymphomas: 23 diffuse large B-cell, and one Burkitt lymphoma. 7.7 % were of T lineage. 13 women and 13 men, had age ranges between 33-71 years (mean 58.16 years). Three patients (12 %) had immunosuppression. Nestin staining revealed hypertrophic astrocytes forming patches about blood vessels with positive cytoplasmic staining in endothelium and pericytes (5-10% of the intra-tumor arterioles). These findings were seen in both B and T lymphomas. OCT4 nuclear expression was only observed in five large B-cell lymphomas and seemed to have relationship with mitoses/HPF (high power field). Conclusion: The novel finding of endothelial, pericytes and hypertrophic astrocytes staining with nestin, points to the involvement of stem cells promoting angiogenesis as a result of a dialogue between neoplastic cells and vascular stem cells. OCT4 expression seems to have a relationship with cell proliferation whose clinical significance should be investigated in prospective studies.

背景:血管生成对肿瘤的生存至关重要。我们的目的是描述我们机构原发性中枢神经系统淋巴瘤(PCNSL)患者的临床特征,并探讨OCT4和巢蛋白在肿瘤微环境中的免疫组织化学表达,特别是与血管生成有关。材料与方法:回顾性分析2016 - 2022年所有PCNSL病例,获取患者临床及影像学特征。采用描述性统计。结果:26例;b细胞淋巴瘤24例(92.3%),其中弥漫性大b细胞淋巴瘤23例,Burkitt淋巴瘤1例。7.7%为T系。13名女性,13名男性,年龄33-71岁(平均58.16岁)。3例(12%)患者存在免疫抑制。巢蛋白染色显示肥大的星形胶质细胞在血管周围形成斑块,内皮细胞和周细胞(肿瘤内小动脉的5-10%)细胞质染色阳性。这些发现在B型和T型淋巴瘤中均可见。OCT4核表达仅在5个大b细胞淋巴瘤中观察到,似乎与有丝分裂/高倍率场有关。结论:内皮细胞、周细胞和肥大星形胶质细胞用巢蛋白染色的新发现表明,由于肿瘤细胞和血管干细胞之间的对话,干细胞参与促进血管生成。OCT4表达似乎与细胞增殖有关,其临床意义有待在前瞻性研究中进一步探讨。
{"title":"OCT4 and Nestin Expression in the Microenvironment of Primary Central Nervous System Lymphomas.","authors":"Ana Laura Calderón-Garcidueñas, Diana Adixa García-Trejo, Noemi Gelista-Herrera, Israel Torres-Ramírez de Arellano","doi":"10.18502/ijhoscr.v19i1.17823","DOIUrl":"10.18502/ijhoscr.v19i1.17823","url":null,"abstract":"<p><p><b>Background:</b> Angiogenesis is essential for the survival of neoplasms. Our aim was to describe the clinical profile of primary central nervous system lymphoma (PCNSL) patients at our institution and explore the immunohistochemical expression of OCT4 and nestin in the tumor microenvironment especially in relation to angiogenesis. <b>Materials and Methods:</b> All cases of PCNSL from 2016 to 2022 were retrospectively studied, and clinical and radiological characteristics of the patients were obtained. Descriptive statistics were used. <b>Results:</b> 26 cases were studied; 24 cases (92.3%) were B-cell lymphomas: 23 diffuse large B-cell, and one Burkitt lymphoma. 7.7 % were of T lineage. 13 women and 13 men, had age ranges between 33-71 years (mean 58.16 years). Three patients (12 %) had immunosuppression. Nestin staining revealed hypertrophic astrocytes forming patches about blood vessels with positive cytoplasmic staining in endothelium and pericytes (5-10% of the intra-tumor arterioles). These findings were seen in both B and T lymphomas. OCT4 nuclear expression was only observed in five large B-cell lymphomas and seemed to have relationship with mitoses/HPF (high power field). <b>Conclusion:</b> The novel finding of endothelial, pericytes and hypertrophic astrocytes staining with nestin, points to the involvement of stem cells promoting angiogenesis as a result of a dialogue between neoplastic cells and vascular stem cells. OCT4 expression seems to have a relationship with cell proliferation whose clinical significance should be investigated in prospective studies.</p>","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"19 1","pages":"43-49"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12103830/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144153073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Age-Related Considerations in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia: A 10-Year Retrospective Study. 同种异体造血干细胞移植治疗急性白血病的年龄相关性:一项10年回顾性研究。
Pub Date : 2025-01-01 DOI: 10.18502/ijhoscr.v19i1.17825
Tanaz Bahri, Mojtaba Azari Alanjeq, Mohammad Vaezi, Ghasem Janbabaei Molla, Fatemeh Tajik Rostami, Maryam Barkhordar, Morteza Azari Alanjeq, Mohammad Biglari, Sahar Tavakoli Shiraji, Soroush Rad, Davoud Babakhani, Mohammadreza Rostami, Seied Asadollah Mousavi, Hosein Kamranzadeh Foumani, Ardeshir Ghavamzadeh

Background: Allogeneic hematopoietic stem cell transplantation (HSCT) has long been a curative intervention for acute leukemia, though outcomes in older patients remain suboptimal due to higher non-relapse mortality (NRM) and relapse rates. Innovations in conditioning regimens and supportive care have made HSCT accessible to patients over 50, but age-related disparities in outcomes persist. Materials and Methods: This 10-year retrospective cohort study reviewed all patients who underwent first-time allogeneic HSCT for acute leukemia. Patients were stratified by age at HSCT (≥ 50 years and < 50 years), and outcomes were assessed for overall survival (OS), disease-free survival (DFS), NRM, and relapse incidence (RI). Results: Of the 1199 patients, 152 were 50 years or older. Five-year OS rates were markedly lower in patients ≥ 50 years compared to younger patients (48.70% vs. 59.35%; P= 0.024 for AML and 23.60% vs. 41.96%; P= 0.025 for ALL). Moreover, older patients demonstrated significantly higher NRM rates (35.95% vs. 23.53%; P= 0.045 for AML and 78.14% vs. 26.76%; P= 0.005 for ALL) and a notably increased incidence of grade III-IV acute graft-versus-host disease (aGVHD). Interestingly, no significant differences were observed between the two age groups regarding DFS rates and RI. Conclusion: Older acute leukemia patients undergoing allogeneic HSCT face significant challenges, including elevated NRM and GVHD rates. While relapse rates were comparable, survival outcomes favored the younger cohort. These findings emphasize the need for age-adapted transplantation strategies, using reduced-intensity conditioning (RIC) regimens and further research to refine risk stratification and improve management approaches for older patients.

背景:异基因造血干细胞移植(HSCT)长期以来一直是治疗急性白血病的一种干预手段,尽管由于较高的非复发死亡率(NRM)和复发率,老年患者的结果仍然不理想。调节方案和支持性护理方面的创新使得50岁以上的患者也可以进行HSCT,但与年龄相关的结果差异仍然存在。材料和方法:这项为期10年的回顾性队列研究回顾了所有首次接受同种异体造血干细胞移植治疗急性白血病的患者。患者按年龄(≥50岁和< 50岁)进行HSCT分层,并评估总生存期(OS)、无病生存期(DFS)、NRM和复发率(RI)。结果:1199例患者中,年龄≥50岁的有152例。≥50岁患者的5年OS率明显低于年轻患者(48.70% vs 59.35%;AML的P= 0.024,分别为23.60%和41.96%;P= 0.025)。此外,老年患者的NRM率显著高于老年患者(35.95% vs. 23.53%;AML的P= 0.045, 78.14% vs. 26.76%;急性淋巴细胞白血病(ALL)发生率P= 0.005, III-IV级急性移植物抗宿主病(aGVHD)发生率显著增加。有趣的是,在DFS率和RI方面,两个年龄组之间没有观察到显著差异。结论:接受同种异体造血干细胞移植的老年急性白血病患者面临重大挑战,包括NRM和GVHD发生率升高。虽然复发率具有可比性,但生存结果更倾向于年轻的队列。这些发现强调了适应年龄的移植策略的必要性,使用降低强度调节(RIC)方案和进一步研究来完善老年患者的风险分层和改进管理方法。
{"title":"Age-Related Considerations in Allogeneic Hematopoietic Stem Cell Transplantation for Acute Leukemia: A 10-Year Retrospective Study.","authors":"Tanaz Bahri, Mojtaba Azari Alanjeq, Mohammad Vaezi, Ghasem Janbabaei Molla, Fatemeh Tajik Rostami, Maryam Barkhordar, Morteza Azari Alanjeq, Mohammad Biglari, Sahar Tavakoli Shiraji, Soroush Rad, Davoud Babakhani, Mohammadreza Rostami, Seied Asadollah Mousavi, Hosein Kamranzadeh Foumani, Ardeshir Ghavamzadeh","doi":"10.18502/ijhoscr.v19i1.17825","DOIUrl":"10.18502/ijhoscr.v19i1.17825","url":null,"abstract":"<p><p><b>Background:</b> Allogeneic hematopoietic stem cell transplantation (HSCT) has long been a curative intervention for acute leukemia, though outcomes in older patients remain suboptimal due to higher non-relapse mortality (NRM) and relapse rates. Innovations in conditioning regimens and supportive care have made HSCT accessible to patients over 50, but age-related disparities in outcomes persist. <b>Materials and Methods:</b> This 10-year retrospective cohort study reviewed all patients who underwent first-time allogeneic HSCT for acute leukemia. Patients were stratified by age at HSCT (≥ 50 years and < 50 years), and outcomes were assessed for overall survival (OS), disease-free survival (DFS), NRM, and relapse incidence (RI). <b>Results:</b> Of the 1199 patients, 152 were 50 years or older. Five-year OS rates were markedly lower in patients ≥ 50 years compared to younger patients (48.70% vs. 59.35%; <i>P</i>= 0.024 for AML and 23.60% vs. 41.96%; <i>P</i>= 0.025 for ALL). Moreover, older patients demonstrated significantly higher NRM rates (35.95% vs. 23.53%; <i>P</i>= 0.045 for AML and 78.14% vs. 26.76%; <i>P</i>= 0.005 for ALL) and a notably increased incidence of grade III-IV acute graft-versus-host disease (aGVHD). Interestingly, no significant differences were observed between the two age groups regarding DFS rates and RI. <b>Conclusion:</b> Older acute leukemia patients undergoing allogeneic HSCT face significant challenges, including elevated NRM and GVHD rates. While relapse rates were comparable, survival outcomes favored the younger cohort. These findings emphasize the need for age-adapted transplantation strategies, using reduced-intensity conditioning (RIC) regimens and further research to refine risk stratification and improve management approaches for older patients.</p>","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"19 1","pages":"60-68"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12103825/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144153065","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiac Considerations in Hematopoietic Stem Cell Transplantation (HSCT) for Transfusion-Dependent Thalassemia: A Review. 造血干细胞移植(HSCT)治疗输血依赖性地中海贫血的心脏考虑:综述。
Pub Date : 2025-01-01 DOI: 10.18502/ijhoscr.v19i1.17826
Saeed Nateghi, Aziz Rasooli, Leila Moaddabshoar, Zahra Panahi, Mohammad Reza Rostami

Hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment option for several malignant and non-malignant hematologic disorders, including transfusion-dependent thalassemia (TDT). However, HSCT is associated with short-term and long-term complications. One of the recognized causes of morbidity and mortality in TDT patients is heart-related complications. Additionally, cardiac involvement is likely to be more common in patients proceeding to HSCT. Thus, the risks of cardiac complications should be carefully weighed against the benefits of the primary disease cure. This review attempted to discuss the cardiac considerations in TDT patients undergoing HSCT.

造血干细胞移植(HSCT)是几种恶性和非恶性血液疾病的潜在治愈治疗选择,包括输血依赖性地中海贫血(TDT)。然而,造血干细胞移植与短期和长期并发症相关。公认的TDT患者发病和死亡的原因之一是心脏相关并发症。此外,心脏受累可能在进行HSCT的患者中更常见。因此,应仔细权衡心脏并发症的风险与原发疾病治疗的益处。这篇综述试图讨论接受HSCT的TDT患者的心脏问题。
{"title":"Cardiac Considerations in Hematopoietic Stem Cell Transplantation (HSCT) for Transfusion-Dependent Thalassemia: A Review.","authors":"Saeed Nateghi, Aziz Rasooli, Leila Moaddabshoar, Zahra Panahi, Mohammad Reza Rostami","doi":"10.18502/ijhoscr.v19i1.17826","DOIUrl":"10.18502/ijhoscr.v19i1.17826","url":null,"abstract":"<p><p>Hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment option for several malignant and non-malignant hematologic disorders, including transfusion-dependent thalassemia (TDT). However, HSCT is associated with short-term and long-term complications. One of the recognized causes of morbidity and mortality in TDT patients is heart-related complications. Additionally, cardiac involvement is likely to be more common in patients proceeding to HSCT. Thus, the risks of cardiac complications should be carefully weighed against the benefits of the primary disease cure. This review attempted to discuss the cardiac considerations in TDT patients undergoing HSCT<b>.</b></p>","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"19 1","pages":"69-74"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12103821/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144153066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
First Experience of Personalized in Situ Tissue Engineering for Thoracic Surgery of the Sarcoma Patient: MSCs-Containing Minimally Manipulated Cells and an Individualized Micropore Titanium Sternum in a One-Year Follow-Up Case Report. 在一项为期一年的随访病例报告中,肉瘤患者胸外科个体化原位组织工程的首次经验:包含mscs的最小操作细胞和个体化微孔钛胸骨。
Pub Date : 2025-01-01 DOI: 10.18502/ijhoscr.v19i1.17830
Ilya V Kolobaev, Vladimir S Usachev, Ilya D Klabukov, Grigoriy V Afonin, Oleg A Aleksandrov, Anna Yu Usacheva, Stanislav S Shklyaev, Lyudmila Yu Grivtsova, Dmitry O Kabanov, Natalia A Rubtsova, Peter V Shegay, Sergei A Ivanov, Andrey D Kaprin, Denis S Baranovskii

Individually customized grafts have become standard for reconstructing extensive chest wall defects resulting from surgical interventions for sternal malignant neoplasms. However, the outcomes of these graft implantations can be further improved by administering patient-derived cells, which have minimal oncological risks. In 2021, a 52-year-old woman with chondrosarcoma (pT2N0M0G2, stage IIB) was admitted to the Department of Thoracic Surgery. The patient presented with a large tumor in the body of the sternum, measuring 81 × 94 × 91 mm, according to the computed tomography (CT) scan. To address this, an individualized endoprosthesis was modeled and created using the original 'pincer-dock' construction based on CT-scan screens. The mononuclear cell fraction (MNCs) was obtained from the patient's peripheral blood one week before surgery using a Haemonetics cell separation device and cryopreserved until the day of the procedure. The resulting 30 mL MNC suspension contained 12 mln cells per 1 mL. We performed flow cytometry analysis using a FACS Aria III flow cytometer to confirm the presence of mesenchymal stromal cells in the MNCs. We also performed immunostaining for S-100, a common tumor marker for benign and malignant diseases, and D2-40, a marker for the lymphatic endothelium that reacts with Kaposi's sarcoma and a subset of angiosarcomas. None of the cells were positive for either marker. Approximately 3 ml of the MNC suspension was injected into each rib edge and 30 ml into the operating field immediately after resection. The titanium endoprosthesis was placed in the sternal defect, and the body of the endoprosthesis was securely covered with a laparoscopically mobilized omental flap. After a one-year follow-up, the patient showed no signs of recurrence or post-surgical complications. These outstanding functional and cosmetic results highlight the potential for the broader clinical utilization of minimally manipulated cells in personalized medicine in oncology. These results could pave the way for wider clinical application of peripheral blood-derived minimally manipulated cells in personalized medicine as an adjuvant for titanium endoprosthesis reconstruction of osteochondral defects in patients with sarcoma.

个别定制的移植物已成为重建胸骨恶性肿瘤手术干预导致的广泛胸壁缺损的标准。然而,这些移植物植入的结果可以通过给予患者来源的细胞进一步改善,这具有最小的肿瘤风险。2021年,一名患有软骨肉瘤(pT2N0M0G2,分期IIB)的52岁女性住进胸外科。根据CT扫描,患者表现为胸骨体大肿瘤,尺寸为81 × 94 × 91 mm。为了解决这个问题,使用基于ct扫描屏幕的原始“钳坞”结构建模并创建了个性化的内假体。使用Haemonetics细胞分离装置在手术前一周从患者外周血中获得单个核细胞分数(MNCs),并冷冻保存至手术当天。所得的30ml MNC悬浮液每1ml含有1200万个细胞。我们使用FACS Aria III流式细胞仪进行流式细胞术分析,以确认MNC中存在间充质间质细胞。我们还对S-100和D2-40进行了免疫染色,S-100是良性和恶性疾病的常见肿瘤标志物,D2-40是淋巴内皮的标志物,与卡波西氏肉瘤和一种血管肉瘤反应。没有细胞对这两种标记物呈阳性。大约3ml的MNC悬浮液注射到每根肋骨边缘,30 ml在切除后立即注射到手术野。在胸骨缺损处置入钛金属假体,假体体用腹腔镜下网膜瓣覆盖。经过一年的随访,患者没有出现复发或术后并发症的迹象。这些突出的功能和美容结果突出了在肿瘤学个体化医疗中更广泛的临床应用最小操作细胞的潜力。这些结果可以为外周血源性微创操作细胞在个性化医疗中的广泛临床应用铺平道路,作为肉瘤患者骨软骨缺损钛假体重建的辅助手段。
{"title":"First Experience of Personalized <i>in Situ</i> Tissue Engineering for Thoracic Surgery of the Sarcoma Patient: MSCs-Containing Minimally Manipulated Cells and an Individualized Micropore Titanium Sternum in a One-Year Follow-Up Case Report.","authors":"Ilya V Kolobaev, Vladimir S Usachev, Ilya D Klabukov, Grigoriy V Afonin, Oleg A Aleksandrov, Anna Yu Usacheva, Stanislav S Shklyaev, Lyudmila Yu Grivtsova, Dmitry O Kabanov, Natalia A Rubtsova, Peter V Shegay, Sergei A Ivanov, Andrey D Kaprin, Denis S Baranovskii","doi":"10.18502/ijhoscr.v19i1.17830","DOIUrl":"10.18502/ijhoscr.v19i1.17830","url":null,"abstract":"<p><p>Individually customized grafts have become standard for reconstructing extensive chest wall defects resulting from surgical interventions for sternal malignant neoplasms. However, the outcomes of these graft implantations can be further improved by administering patient-derived cells, which have minimal oncological risks. In 2021, a 52-year-old woman with chondrosarcoma (pT2N0M0G2, stage IIB) was admitted to the Department of Thoracic Surgery. The patient presented with a large tumor in the body of the sternum, measuring 81 × 94 × 91 mm, according to the computed tomography (CT) scan. To address this, an individualized endoprosthesis was modeled and created using the original 'pincer-dock' construction based on CT-scan screens. The mononuclear cell fraction (MNCs) was obtained from the patient's peripheral blood one week before surgery using a Haemonetics cell separation device and cryopreserved until the day of the procedure. The resulting 30 mL MNC suspension contained 12 mln cells per 1 mL. We performed flow cytometry analysis using a FACS Aria III flow cytometer to confirm the presence of mesenchymal stromal cells in the MNCs. We also performed immunostaining for S-100, a common tumor marker for benign and malignant diseases, and D2-40, a marker for the lymphatic endothelium that reacts with Kaposi's sarcoma and a subset of angiosarcomas. None of the cells were positive for either marker. Approximately 3 ml of the MNC suspension was injected into each rib edge and 30 ml into the operating field immediately after resection. The titanium endoprosthesis was placed in the sternal defect, and the body of the endoprosthesis was securely covered with a laparoscopically mobilized omental flap. After a one-year follow-up, the patient showed no signs of recurrence or post-surgical complications. These outstanding functional and cosmetic results highlight the potential for the broader clinical utilization of minimally manipulated cells in personalized medicine in oncology. These results could pave the way for wider clinical application of peripheral blood-derived minimally manipulated cells in personalized medicine as an adjuvant for titanium endoprosthesis reconstruction of osteochondral defects in patients with sarcoma.</p>","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"19 1","pages":"86-92"},"PeriodicalIF":0.0,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12103829/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144153069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Infected Primary Bone Mantle Cell Lymphoma with Multiple Vertebral Involvement. 累及多个椎体的感染原发性骨套细胞淋巴瘤。
Pub Date : 2024-10-01 DOI: 10.18502/ijhoscr.v18i4.16765
Rebeh Bougossa, Fatma Larbi, Asma Ben Mabrouk, Olfa Jomaa, Jihene Chelli

Primary vertebral lymphoma is an exceedingly rare entity. We hereby report a case of a 67-year-old male who presented to our department with fever, weight loss, and progressively worsening lower back pain radiating to the right hip. Physical examination showed pain on percussion of the dorsal and lumbar spine and tenderness on palpation of the right upper thigh area. The radiographic findings revealed numerous vertebral lesions with a right psoas abscess extending to the right upper thigh. Intravenous antibiotic therapy was initiated and the patient underwent an incision and drainage of the psoas abscess with a favourable outcome. However, given the suspicious imaging findings of the osseous lesions suggestive of malignancy, a vertebral biopsy was performed and yielded histo-pathological findings consistent with bone mantle cell lymphoma. To the best of our knowledge, this is the first case of an infected primary bone mantle cell lymphoma with multiple vertebral involvement. The diagnosis is challenging and can be confused with other diseases.

原发性椎体淋巴瘤是一种极为罕见的疾病。我们在此报告一例67岁男性患者,他以发热、体重减轻和逐渐恶化的腰痛向右髋部放射就诊。体格检查显示脊背和腰椎触痛,右大腿上部触痛。x线表现显示许多椎体病变,右腰肌脓肿延伸至右大腿上部。开始静脉注射抗生素治疗,患者接受腰肌脓肿切开引流,结果良好。然而,考虑到可疑的骨病变影像学结果提示恶性肿瘤,我们进行了椎体活检,结果显示组织病理结果与骨套细胞淋巴瘤一致。据我们所知,这是第一例感染原发性骨套细胞淋巴瘤累及多椎体的病例。诊断具有挑战性,并可能与其他疾病混淆。
{"title":"Infected Primary Bone Mantle Cell Lymphoma with Multiple Vertebral Involvement.","authors":"Rebeh Bougossa, Fatma Larbi, Asma Ben Mabrouk, Olfa Jomaa, Jihene Chelli","doi":"10.18502/ijhoscr.v18i4.16765","DOIUrl":"10.18502/ijhoscr.v18i4.16765","url":null,"abstract":"<p><p>Primary vertebral lymphoma is an exceedingly rare entity. We hereby report a case of a 67-year-old male who presented to our department with fever, weight loss, and progressively worsening lower back pain radiating to the right hip. Physical examination showed pain on percussion of the dorsal and lumbar spine and tenderness on palpation of the right upper thigh area. The radiographic findings revealed numerous vertebral lesions with a right psoas abscess extending to the right upper thigh. Intravenous antibiotic therapy was initiated and the patient underwent an incision and drainage of the psoas abscess with a favourable outcome. However, given the suspicious imaging findings of the osseous lesions suggestive of malignancy, a vertebral biopsy was performed and yielded histo-pathological findings consistent with bone mantle cell lymphoma. To the best of our knowledge, this is the first case of an infected primary bone mantle cell lymphoma with multiple vertebral involvement. The diagnosis is challenging and can be confused with other diseases.</p>","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"18 4","pages":"403-406"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11652700/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hematologic Parameters Cut-off Assessment of Adult Alpha-Thalassemia Patients in Iran. 伊朗成人α -地中海贫血患者血液学参数临界值评估。
Pub Date : 2024-10-01 DOI: 10.18502/ijhoscr.v18i4.16757
Bijan Keikhaei, Saeid Bitaraf, Ladan Mafakher, Hamid Galehdari, Amal Saki-Malehi, Mohammad Bahadoram

Background: Thalassemia is one of the most common blood disorders in Iran. Alpha-thalassemia is caused by the deletion of the alpha-globin gene. The frequency of deletions in the alpha-globin gene is associated with microcytosis and hypochromia, making hematological parameters valuable predictive tools in the initial identification of alpha-thalassemia patients. This study aimed to compare hematologic parameters such as Mean Corpuscular Volume (MCV), Mean Corpuscular Hemoglobin (MCH), red blood cell (RBC) count, and hemoglobin (HGB) levels in silent and minor patients, whose genotypes were genetically characterized, with normal patients to establish cut-off points for these groups. Materials and Methods: The study involved a total of 860 patients with alpha-thalassemia, including 267 cases of silent, 261 cases of minor, and 332 cases of normal alpha-thalassemia. Results: Analysis of blood indices based on sex revealed that the male group had higher values than the female group. Assessment of alpha-thalassemia in minor patients showed that the Cis form (-/αα) had higher microcytosis than the Trans form (-α/-α) in this group. This difference was also observed between α-3.7α/ α-3.7α and (αα)-MED/αα as two different genetic forms in minor patients, with (αα)-MED/αα being in the Cis form. Data indicated that the cut-off value was insignificant in silent patients compared to the normal group. However, minor patients with MCH≤23.7 and MCV≤74.9 had an AUC greater than 0.9 (p-value< 0.01), distinguishing them from the normal group. Conclusion: Comparing hematological parameters in these groups illustrated that MCV and MCH are the best predictor parameters for distinguishing between groups.

背景:地中海贫血是伊朗最常见的血液疾病之一。地中海贫血是由α -珠蛋白基因缺失引起的。α -珠蛋白基因缺失的频率与小细胞增多和低色素血症有关,使血液学参数在α -地中海贫血患者的初步鉴定中有价值的预测工具。本研究旨在比较沉默和轻微患者的血液学参数,如平均红细胞体积(MCV),平均红细胞血红蛋白(MCH),红细胞(RBC)计数和血红蛋白(HGB)水平,其基因型具有遗传特征,与正常患者建立这些组的截止点。材料与方法:本研究共纳入860例α -地中海贫血患者,其中无症状型267例,轻度261例,正常型332例。结果:基于性别的血液指标分析显示,男性组高于女性组。对少数患者α -地中海贫血的评估显示,顺式(-/αα)比反式(-α/-α)有更高的小细胞增生。α-3.7α/ α-3.7α和(αα)-MED/αα作为两种不同的遗传形式在未成年患者中也存在差异,其中(αα)-MED/αα为Cis形式。数据显示,与正常组相比,沉默患者的临界值不显著。而MCH≤23.7、MCV≤74.9的未成年患者AUC大于0.9 (p值< 0.01),与正常组有明显区别。结论:比较各组血液学指标,MCV和MCH是区分两组的最佳预测指标。
{"title":"Hematologic Parameters Cut-off Assessment of Adult Alpha-Thalassemia Patients in Iran.","authors":"Bijan Keikhaei, Saeid Bitaraf, Ladan Mafakher, Hamid Galehdari, Amal Saki-Malehi, Mohammad Bahadoram","doi":"10.18502/ijhoscr.v18i4.16757","DOIUrl":"10.18502/ijhoscr.v18i4.16757","url":null,"abstract":"<p><p><b>Background:</b> Thalassemia is one of the most common blood disorders in Iran. Alpha-thalassemia is caused by the deletion of the alpha-globin gene. The frequency of deletions in the alpha-globin gene is associated with microcytosis and hypochromia, making hematological parameters valuable predictive tools in the initial identification of alpha-thalassemia patients. This study aimed to compare hematologic parameters such as Mean Corpuscular Volume (MCV), Mean Corpuscular Hemoglobin (MCH), red blood cell (RBC) count, and hemoglobin (HGB) levels in silent and minor patients, whose genotypes were genetically characterized, with normal patients to establish cut-off points for these groups. <b>Materials and Methods:</b> The study involved a total of 860 patients with alpha-thalassemia, including 267 cases of silent, 261 cases of minor, and 332 cases of normal alpha-thalassemia. <b>Results:</b> Analysis of blood indices based on sex revealed that the male group had higher values than the female group. Assessment of alpha-thalassemia in minor patients showed that the Cis form (-/αα) had higher microcytosis than the Trans form (-α/-α) in this group. This difference was also observed between α<sup>-3.7</sup>α/ α<sup>-3.7</sup>α and (αα)<sup>-MED</sup>/αα as two different genetic forms in minor patients, with (αα)<sup>-MED</sup>/αα being in the Cis form. Data indicated that the cut-off value was insignificant in silent patients compared to the normal group. However, minor patients with MCH≤23.7 and MCV≤74.9 had an AUC greater than 0.9 (p-value< 0.01), distinguishing them from the normal group. <b>Conclusion:</b> Comparing hematological parameters in these groups illustrated that MCV and MCH are the best predictor parameters for distinguishing between groups.</p>","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"18 4","pages":"323-329"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11652692/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sequential Occurrence of Eosinophilic Gastrointestinal Disease in a Case of Waldenström's Macroglobulinemia in Remission: An Unusual Report with Review. 一例处于缓解期的瓦尔登斯特伦巨球蛋白血症患者相继出现嗜酸性粒细胞胃肠病:一份不寻常的报告与回顾
Pub Date : 2024-10-01 DOI: 10.18502/ijhoscr.v18i4.16767
Ankit Jitani, Mayur Babasaheb Mundhe, Kazi Wajid Husain, Hemant Menghani, Maharshi Desai, Velu Nair

Waldenström macroglobulinemia (WM) is a rare lymphoproliferative malignancy presenting with para-proteinemia. The symptoms are attributable to both lymphoproliferation and IgM flare. Gastrointestinal manifestations are not uncommon. It is an indolent disease with good response to chemoimmunotherapy but with possible persistence of asymptomatic paraproteinemia. Resurgence of gastrointestinal symptoms in a patient of WM maintaining reasonable response warrant a thorough search for alternate pathology. Herein we describe a rare case of sequential occurrence of WM with Eosinophilic Gastrointestinal Disease posing a diagnostic and therapeutic challenge.

Waldenström巨球蛋白血症(WM)是一种罕见的淋巴细胞增生性恶性肿瘤,表现为类蛋白血症。这些症状可归因于淋巴细胞增生和IgM爆发。胃肠道表现并不罕见。它是一种惰性疾病,对化学免疫治疗反应良好,但可能持续存在无症状的副蛋白血症。WM患者维持合理反应的胃肠道症状再次出现,需要彻底寻找其他病理。在这里,我们描述了一个罕见的病例顺序发生WM与嗜酸性胃肠道疾病提出诊断和治疗的挑战。
{"title":"Sequential Occurrence of Eosinophilic Gastrointestinal Disease in a Case of Waldenström's Macroglobulinemia in Remission: An Unusual Report with Review.","authors":"Ankit Jitani, Mayur Babasaheb Mundhe, Kazi Wajid Husain, Hemant Menghani, Maharshi Desai, Velu Nair","doi":"10.18502/ijhoscr.v18i4.16767","DOIUrl":"10.18502/ijhoscr.v18i4.16767","url":null,"abstract":"<p><p>Waldenström macroglobulinemia (WM) is a rare lymphoproliferative malignancy presenting with para-proteinemia. The symptoms are attributable to both lymphoproliferation and IgM flare. Gastrointestinal manifestations are not uncommon. It is an indolent disease with good response to chemoimmunotherapy but with possible persistence of asymptomatic paraproteinemia. Resurgence of gastrointestinal symptoms in a patient of WM maintaining reasonable response warrant a thorough search for alternate pathology. Herein we describe a rare case of sequential occurrence of WM with Eosinophilic Gastrointestinal Disease posing a diagnostic and therapeutic challenge.</p>","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"18 4","pages":"411-414"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11652698/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Allogeneic Stem Cell Transplant in Hematological Disorders: A Decade of Experience. 同种异体干细胞移植治疗血液病:十年经验。
Pub Date : 2024-10-01 DOI: 10.18502/ijhoscr.v18i4.16759
Salman Arif, Natasha Ali, Usman Shaikh, Salman Adil, Hamzah Jehanzeb

Background: Allogeneic hematopoietic cell transplantation (allo-HCT) is a complex procedure with the potential to provide curative treatment for various hematological disorders. This study aims to evaluate the outcomes of allo-HCT in hematological diseases and identify significant complications in a single-center setting. Materials and Methods: We conducted a retrospective analysis of 180 patients with hematological diseases who underwent allo-HCT between January 2011 and December 2021. Key outcomes, including indications for transplantation, overall survival, engraftment time, relapse rates, graft-versus-host disease (GVHD), and transplant-related mortality (TRM) were assessed. Results: The most common indications for allo-HCT were benign hematological diseases, particularly aplastic anemia, and thalassemia major. Despite the majority of patients receiving fully matched transplants, acute GVHD was observed in 30% of the cohort. Graft failure occurred in 13 patients, with primary and secondary graft failure rates of 1.6% and 5.5%, respectively. Sepsis emerged as the primary cause of non-relapsed mortality at day 100 and beyond. The overall survival rate in this study was 62%, with 79% of patients disease-free on their last visit. Conclusion: This study provides valuable insights into the treatment strategies and patient care of allo-HCT for hematological disorders by offering a comprehensive overview of multiple relevant outcomes. The findings underscore the significance of addressing complications and risk factors associated with allogeneic transplantation, including GVHD and infections. Future research should focus on further optimizing transplantation techniques to minimize complications and enhance patient survival.

背景:同种异体造血细胞移植(Allogeneic hematopoietic cell transplantation, allo-HCT)是一项复杂的手术,有可能为各种血液疾病提供根治性治疗。本研究旨在评估同种异体hct在血液学疾病中的效果,并在单中心环境中确定显著并发症。材料和方法:我们对2011年1月至2021年12月期间接受同种异体hct治疗的180例血液病患者进行了回顾性分析。主要结果包括移植适应症、总生存期、移植时间、复发率、移植物抗宿主病(GVHD)和移植相关死亡率(TRM)。结果:同种异体hct最常见的适应症是良性血液系统疾病,尤其是再生障碍性贫血和重度地中海贫血。尽管大多数患者接受了完全匹配的移植,但在30%的队列中观察到急性GVHD。13例患者发生移植物衰竭,原发性和继发性移植物失败率分别为1.6%和5.5%。脓毒症成为第100天及以后非复发性死亡的主要原因。该研究的总生存率为62%,79%的患者在最后一次就诊时无疾病。结论:本研究通过对多种相关结果的全面概述,为同种异体hct治疗血液系统疾病的治疗策略和患者护理提供了有价值的见解。研究结果强调了解决与同种异体移植相关的并发症和危险因素的重要性,包括GVHD和感染。未来的研究应着眼于进一步优化移植技术,以减少并发症,提高患者生存率。
{"title":"Allogeneic Stem Cell Transplant in Hematological Disorders: A Decade of Experience.","authors":"Salman Arif, Natasha Ali, Usman Shaikh, Salman Adil, Hamzah Jehanzeb","doi":"10.18502/ijhoscr.v18i4.16759","DOIUrl":"10.18502/ijhoscr.v18i4.16759","url":null,"abstract":"<p><p><b>Background</b>: Allogeneic hematopoietic cell transplantation (allo-HCT) is a complex procedure with the potential to provide curative treatment for various hematological disorders. This study aims to evaluate the outcomes of allo-HCT in hematological diseases and identify significant complications in a single-center setting. <b>Materials and Methods</b>: We conducted a retrospective analysis of 180 patients with hematological diseases who underwent allo-HCT between January 2011 and December 2021. Key outcomes, including indications for transplantation, overall survival, engraftment time, relapse rates, graft-versus-host disease (GVHD), and transplant-related mortality (TRM) were assessed. <b>Results</b>: The most common indications for allo-HCT were benign hematological diseases, particularly aplastic anemia, and thalassemia major. Despite the majority of patients receiving fully matched transplants, acute GVHD was observed in 30% of the cohort. Graft failure occurred in 13 patients, with primary and secondary graft failure rates of 1.6% and 5.5%, respectively. Sepsis emerged as the primary cause of non-relapsed mortality at day 100 and beyond. The overall survival rate in this study was 62%, with 79% of patients disease-free on their last visit. <b>Conclusion</b>: This study provides valuable insights into the treatment strategies and patient care of allo-HCT for hematological disorders by offering a comprehensive overview of multiple relevant outcomes. The findings underscore the significance of addressing complications and risk factors associated with allogeneic transplantation, including GVHD and infections. Future research should focus on further optimizing transplantation techniques to minimize complications and enhance patient survival.</p>","PeriodicalId":94048,"journal":{"name":"International journal of hematology-oncology and stem cell research","volume":"18 4","pages":"344-357"},"PeriodicalIF":0.0,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11652702/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142866836","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
International journal of hematology-oncology and stem cell research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1